Hematologic Malignancies and Novel Therapeutic Modalities

• 4510 · PDF Comprehensive surfaceome proteomics uncovers CD70 as a novel immunotherapeutic target in natural killer/T cell lymphoma (NKTL) Ern Sen Chew, Nurulhuda Mustafa, Wai Khang Yong, Vartika Khanchandani, Rui Xue Lee, Anand Jeyasekharan, Dennis Kappei, Siok Bian Ng, Wee Joo Chng
• 4511 · PDF Dual targeting of IKKbeta and NR4A1 for AML therapy Chandra Kumar Maharjan, Yi Liu, Yufeng Xiao, Bristy Podder, Tyler Montgomery, Lei Wang, Myung-Chul Kim, Zeng Jin, Seyedehalaleh Anvar, Alexandra Stevens, Ryan Kolb, Chen Zhao, Zhijian Qian, Jatinder K. Lamba, Guangrong Zheng, Weizhou Zhang
• 4512 · PDF WASP activation by BM011 triggers mitochondrial collapse and aldolase-dependent glycolytic vulnerability in lymphoma Filippo Spriano, Luciano Cascione, Stephen Croke, Digvijay Gahtory, Maurits van den Nieuwboer, Francesco Bertoni
• 4513 · PDF Structural surface protein targets for AML James Dowell, Daniel Benjamin, Patric Sadecki, Jonathan Schmitz, Anjali Nelliat, Anna Ritter, Neal C. Goodwin
• 4514 4514 Development and validation of a CyTOF assay for measuring phosphoproteins in AML blast cell populations in whole blood from AML patients Steven R. Pirie-Shepherd, Crystal Tarrago, Wenxin Zheng, Sen Zhang, Hamish Wright
• 4515 · PDF Clinically relevant AML modeling with in vitro bone marrow niche and in vivo PDX approaches Talita Stessuk, Hanna Vermeer, Afsaneh Golestani, Jolie Flach, Jessie Wang, Qingzhi Liu, Jinping Liu, Gera Goverse, Marrit Putker, Ludovic Bourre
• 4517 4517 Triamterene inhibits NRF2 Mut as a molecular glue Yahui Li, Zachary Ladd, Haining Wang, Candice Bui-Linh, Boopathi Subramaniyan, Chorlada Paiboonrungruang, Huan Li, Yan Ma, Kiera Chang, Katherine Gao, Maiya Ang, Francis Spitz, Zhaohui Xiong, Xiaoxin Luke Chen
• 4518 4518 Preclinical assessment of BT5528 anti-tumor activity in patient-derived xenograft (PDX) models of pancreatic ductal adenocarcinoma (PDAC) Lukas Stanczuk, Assunta De Rienzo, Gavin Bennett
• 4519 · PDF FS-207: A potential best-in-class WRN helicase inhibitor for treating MSI-H cancers Bin Li, Cai Wu, Yaqian Liu, Linsen Li, Yan Ma, Dongbo Li
• 4520 · PDF Development of terfenadine-derived small-molecule inhibitors of TFE3-O dimerization for translocation renal cell carcinoma Christian Migliarese, Mohd Abdullaha, Ilaria Delle Fontane, David E. Heppner, Roberto Pili
• 4521 4521 Use of a p120 RasGAP glue to inhibit KRas in NF1-null cells Anastasiia Gerasimova, Sven Miller, Jonathan Chernoff
• 4522 4522 Advancing protein engineering through AcroAIxTM: AI-driven strategies for enhanced structure and function optimization Spencer Chiang, Jane Liu, Lisa Chou, An Ouyang, Lili Qin
• 4524 · PDF LDHA-positive neutrophils drive Treg-mediated immune tolerance to promote resistance to pan-RAS inhibitors in pancreatic cancer Xiangyan Jiang, Xiaoe He, Wen Wei, Qichen He, Lei Shi, Zuoyi Jiao
• 4525 · PDF Potential of Rac and Cdc42 inhibitors as pancreatic cancer therapeutics Anamaris Torres-Sanchez, Ailed Cruz-Collazo, Nilmary Grafals, Stephanie Dorta-Estremera, Suranganie Dharmawardhane Flanagan
• 4526 · PDF Activation of the RXR nuclear receptor improves survival and the therapeutic window of immunotherapy in murine breast cancer Ana S. Leal
• 4528 4528 The basal cell-derived matricellular protein SPON2 suppresses luminal cell oxidative phosphorylation and cancer progression by blocking the SLC38A1/mTOR metabolic axis Pengfei (Paul) Lu
• 4529 · PDF Antibody-drug conjugates for the treatment of hematologic malignancies Priya Hays
• 4530 · PDF Synergistic targeting of Mediator complex and BCL-2 reveals a novel therapeutic strategy for acute myeloid leukemia Camille Aitchedji, Céline Moison, Deanne Gracias, Rodrigo Mendoza-Sanchez, Simon Fortier, Jean-François Spinella, Tara Macrae, Nadine Mayotte, Mélanie Frechette, Valérie Blouin-Chagnon, Koryne Leveillé, Réjean Ruel, Anne Marinier, Guy Sauvageau, Josée Hébert

在会议检索中浏览本分会场